![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale](https://i1.rgstatic.net/publication/23267285_Better_sexual_acceptability_of_agomelatine_25_and_50_mg_compared_with_paroxetine_20_mg_in_healthy_male_volunteers_An_8-week_placebo-controlled_study_using_the_PRSEXDQ-SALSEX_scale/links/0fcfd50216cd106508000000/largepreview.png)
PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale
![Agomelatine versus other antidepressive agents for major depression - Guaiana, G - 2013 | Cochrane Library Agomelatine versus other antidepressive agents for major depression - Guaiana, G - 2013 | Cochrane Library](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008851.pub2/media/CDSR/CD008851/image_n/nCD008851-CMP-001-26.png)
Agomelatine versus other antidepressive agents for major depression - Guaiana, G - 2013 | Cochrane Library
![Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/916006ff-1a18-4c85-9394-7073a356dd1e/brb32311-fig-0001-m.jpg)
Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library
![PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder](https://i1.rgstatic.net/publication/353632699_Drug_use_evaluation_A_two-year_retrospective_review_of_the_effectiveness_and_tolerability_of_agomelatine_versus_mirtazapine_in_patients_with_depressive_disorder/links/61076e170c2bfa282a15b72d/largepreview.png)
PDF) Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
![PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression](https://i1.rgstatic.net/publication/263459484_Use_of_Valdoxan_Agomelatin_in_the_Combined_Treatment_of_Moderate_and_Severe_Nonpsychotic_Depression/links/57beb3c408aed246b0f75900/largepreview.png)
PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression
![PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression](https://www.researchgate.net/profile/Vladimir-Medvedev/publication/263459484/figure/tbl1/AS:667640527867926@1536189314523/Distribution-of-Patients-Depending-on-Additional-Agents-Used-in-Combination-with_Q320.jpg)
PDF) Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression
![IJMS | Free Full-Text | The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice IJMS | Free Full-Text | The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice](https://pub.mdpi-res.com/ijms/ijms-14-12458/article_deploy/html/images/ijms-14-12458f1.png?1403146582)